A1 Refereed original research article in a scientific journal
Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors
Authors: Jokinen E.M., Postila P.A., Ahinko M., Niinivehmas S., Pentikäinen O.T.
Publisher: WILEY
Publication year: 2019
Journal: Chemical Biology and Drug Design
Journal name in source: CHEMICAL BIOLOGY & DRUG DESIGN
Journal acronym: CHEM BIOL DRUG DES
Volume: 94
Issue: 4
First page : 1799
Last page: 1812
Number of pages: 14
ISSN: 1747-0277
eISSN: 1747-0285
DOI: https://doi.org/10.1111/cbdd.13584(external)
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/42093050(external)
A novel virtual screening methodology called fragment- and negative image-based (F-NiB) screening is introduced and tested experimentally using phosphodiesterase 10A (PDE10A) as a case study. Potent PDE10A-specific small-molecule inhibitors are actively sought after for their antipsychotic and neuroprotective effects. The F-NiB combines features from both fragment-based drug discovery and negative image-based (NIB) screening methodologies to facilitate rational drug discovery. The selected structural parts of protein-bound ligand(s) are seamlessly combined with the negative image of the target's ligand-binding cavity. This cavity- and fragment-based hybrid model, namely its shape and electrostatics, is used directly in the rigid docking of ab initio generated ligand 3D conformers. In total, 14 compounds were acquired using the F-NiB methodology, 3D quantitative structure-activity relationship modeling, and pharmacophore modeling. Three of the small molecules inhibited PDE10A at similar to 27 to similar to 67 mu M range in a radiometric assay. In a larger context, the study shows that the F-NiB provides a flexible way to incorporate small-molecule fragments into the drug discovery.
Downloadable publication This is an electronic reprint of the original article. |  |
